Korea LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son, explains the reason why he joined the company, his strategy to turn it into a truly global entity, and its…
Spain Albert Barberá, director general of research and innovation in health for the Government of Catalonia, highlights his top priorities to facilitate the growth of the Catalan innovation scene and how he plans to transfer this to the healthcare system. Furthermore, he explains the importance of providing smaller companies with the…
Opinion Brendan Shaw is principal at Shawview Consulting, a specialised consulting and advisory firm for public and private sector leaders in the areas of government-business relations, policy and strategic change, with a focus on the health and pharmaceutical sectors. He is also Adjunct Senior Lecturer in Pharmaceutical Medicine, School of Medical Sciences…
Korea Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country Caretaker) service allows smaller firms to overcome regulatory barriers without having to set up an affiliate years prior to a…
Spain Cristina Garmendia, president of the Cotec Foundation, gives an overview of the innovation landscape in Spain and the steps needed to see this grow in the future. Furthermore, she gives advice based on her experiences with Genetrix, a company recently sold to Takeda, and she highlights what is next in…
Opinion Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI) in Europe, outlines the value of public-private partnerships in drug research and development and highlights areas where these collaborations are proving their worth in overcoming some of the most challenging threats to our health. Our collective ability to translate…
Opinion Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in innovative biopharmaceutical companies in Canada. I’ve often wondered how things would be if Canada had steadily continued a path of biopharmaceutical discovery and commercialization after Banting and Best’s breakthrough in 1921, and what…
Korea SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview, Jeong Woo Cho PhD, CEO & president of SK Biopharmaceuticals and SK Life Science, provides an overview of the current…
China Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative commercial partnerships he has established with leading health insurance companies in China. My medical knowledge is limited. But I…
Spain Staffan Schüberg, CEO of Esteve, highlights the restructure of the company as it moves towards its new age of being a truly innovative pharmaceutical company on a global level. Furthermore, he highlights the international strategy and the role the US market will play in the future, as well as his…
Spain Sergio Rodriguez, CEO of Pfizer Spain, highlights the strength of the affiliate and the importance for the company in Europe, as well as the key areas that are driving their growth. Furthermore, he gives an overview of the need for innovative companies to partner with key stakeholders and illustrates what…
Spain Dr Juan Abarca Cidón, president of HM Hospitales, one of Spain’s leading private health groups, gives insight into the private health sector of the country, its relation to the public system, and the opportunities that exist to interact. Dr Abarca goes on to discuss the R&D capabilities of the group…
See our Cookie Privacy Policy Here